相关概念视频
Mismatch Repair
43.5K
Overview
43.5K
Mismatch Repair
6.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Proofreading
8.6K
Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore, it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase...
Errors During Replication are Corrected by the DNA Polymerase...
8.6K
Proofreading
59.7K
Overview
59.7K
Long-patch Base Excision Repair
7.8K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.8K
您也可能阅读
相关文章
通过共同作者、期刊和引用图与本文相关的文章。
排序
Same author
Urinary and Plasma KIM-1 in Chronic Kidney Disease: Prognostic Insights and Remaining Questions.
American journal of nephrology·2025
Same journal
Expert Commentary of the Recent International Pediatric Nephrology Association IgA Vasculitis Nephritis Guidelines.
Nephron·2026
Same journal
Acute effects of exercise on the nephron index under different conditions in middle-aged males - a preliminary study.
Nephron·2026
Same journal
Lysozyme-Associated Nephropathy in Myeloid Neoplasms: A Clinicopathological and Mass Spectrometric Study of Two Cases.
Nephron·2026
Same journal
Prevalence of COVID-19 Pneumonia and Clinical Characteristics in Hemodialysis Patients During the SARS-CoV-2 Omicron Pandemic.
Nephron·2026
Same journal
Real-World Outcomes of Patients with Monoclonal Gammopathy of Renal Significance.
Nephron·2026
概括
反应性C蛋白与蛋白的比率预测了接受连续置换治疗的急性损伤患者的死亡率. 这种炎症标志物为重症监护 nefrology 提供了有价值的预后信息.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 临界护理医学 临界护理医学
- 生物标志物 生物标志物
背景情况:
- 急性损伤 (AKI) 是一个重大的临床挑战.
- 持续置换疗法 (CRRT) 用于严重的AKI.
- 在CRRT的AKI患者中确定预后标志物至关重要.
研究的目的:
- 研究需要CRRT的AKI患者中C-反应蛋白与白蛋白比率 (CAR) 和死亡率之间的关联.
- 评估CAR作为预测性生物标志物,用于该患者群体的结果.
主要方法:
- 多中心回顾性研究设计.
- 包括患有需要CRRT的AKI的成年患者.
- 对基线C反应蛋白和白蛋白水平的分析,以计算CAR.
- 统计分析以确定CAR和住院死亡率之间的相关性.
主要成果:
- 基线C反应性蛋白与白蛋白比率升高与死亡率增加有显著的关联.
- 在CRRT治疗中,CAR证明了AKI患者死亡率的独立预测值.
- 该研究将CAR确定为潜在的预后指标.
结论:
- 反应性C蛋白与白蛋白的比率是一个易于获得和有用的生物标志物,用于预测接受CRRT的重症患者的死亡率.
- 将CAR纳入风险分层可能会改善患者管理和结果.


